Flynn James E
SEC Form 4 insider trading activity
Flynn James E has filed 4 SEC Form 4 filings (15 transaction rows) across 3 companies, including NUVL, PBLS, LRMR, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jun 18, 2026.
On the most recent filing, Flynn James E is listed as Director, 10% Owner at Larimar Therapeutics, Inc. Inside the rolling window, Flynn James E reported 1 open-market purchase totaling $25.0M in LRMR and 1 open-market sale totaling $35.4M in NUVL. The largest disclosed transaction in the window is a sale of 371,287 NUVL shares on Nov 24, 2025, worth $35.4M.
Companies traded
Other insiders at NUVL
Insider Buying
$25.0M
reported purchases (SEC code P)
Insider Selling
$35.4M
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Flynn James E made?
Flynn James E has filed 4 SEC Form 4 filings (15 transaction rows) across 3 companies, including NUVL, PBLS, LRMR since 2025.
Which companies does Flynn James E trade?
Flynn James E has filed SEC Form 4 disclosures for 3 companies, including NUVL, PBLS, LRMR.
When was Flynn James E's most recent SEC Form 4 filing?
Flynn James E's most recent SEC Form 4 filing on Tracefour is dated Jun 18, 2026.
What is Flynn James E's total buy and sell value in the current window?
Inside the rolling retention window, Flynn James E bought $25.0M and sold $35.4M based on SEC Form 4 filings.
What was Flynn James E's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 371,287 NUVL shares on 2025-11-24, worth $35.4M, per SEC Form 4 filings.